Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novo Nordisk Lays Out Obesity Commercial Strategy, Ahead of Liraglutide FDA Submission

This article was originally published in The Pink Sheet Daily

Executive Summary

Reimbursement and sales strategy for liraglutide 3 mg to treat obesity, which the pharma hopes to launch in 2015, are a focus as the pharma laid out its long-term plans in an analyst meeting on Dec. 3. It suggested payers, who aren’t embracing new obesity drugs, could try patients on the drug for a trial period and proceed only with the best responders.


Related Content

Orexigen Hopes FDA Sees The LIGHT On Contrave NDA
Novo Is On Track To File Liraglutide For Obesity By 2014


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts